Nā huahana

ʻO ka neuroblastoma, kahi maʻi maʻi o ka pūnaeho puʻuwai aloha, ʻo ia ka maʻi maʻamau extracranial solid i nā keiki.ʻO ka hoʻonuiʻana o MYCN a me ka hoʻonuiʻana i ka hōʻailona BDNF / TrkB he mau hiʻohiʻona o nā maʻi koko kiʻekiʻe;akā naʻe, ʻo ˜25% wale nō o nā maʻi maʻi ʻino e hōʻike i kēia mau hiʻohiʻona.No laila, pono ka ʻike ʻana i nā biomarkers hou aʻe a me nā pahuhopu therapeutic.ʻOiai ʻo aminoacylase 1 (ACY1), he amino acid deacetylase, he mea hoʻopau i ka maʻi maʻi i loko o ka ʻōpū liʻiliʻi a me nā maʻi maʻi maʻi renal cell, ua noiʻi mākou inā hiki iā ia a i ʻole nā ​​​​ʻohana ʻē aʻe aspartoacylase (ASPA, aminoacylase 2) a i ʻole aminoacylase 3 (ACY3). he hana like ma neuroblastoma.Ua nānā ʻia ka ʻōlelo Aminoacylase ma TrkB-positive, MYCN-amplified (SMS-KCNR a me SK-N-BE) a me TrkB-negative, non-MYCN-amplified (SK-N-AS, SK-N-SH, SH-SY5Y a me SH-EP) nā laina pūnaewele neuroblastoma.Hōʻike kēlā me kēia aminoacylase i ka hoʻokaʻawale spatial localization (ʻo ia hoʻi, cytosolic ACY1, ASPA pili i ka membrane a me ACY3 nuklea).I ka mālama ʻia ʻana o nā pūnaewele SK-N-SH me nā mea hoʻokaʻawale neural (e laʻa, ka waika retinoic a me ka cAMP) i loko o ka media i loaʻa ka 10% serum, ʻo ACY1 wale nō ka aminoacylase nona ka ʻōlelo i hoʻoponopono ʻia.Ua hōʻike mua ʻia ʻo ASPA i nā cell SH-EP o kahi sublineage glial.Ua hōʻike nui ʻia ka ACY3 ma nā laina TrkB-positive, MYCN-amplified.ʻO nā aminoacylases ʻekolu i hōʻike ʻia i loko o ke kanaka adrenal gland maʻamau, kahi kahua maʻamau o ka neuroblastoma kumu, akā ʻo ACY1 a me ACY3 wale nō i hōʻike ʻia i ka ʻike ʻike ʻia i ka maʻi neuroblastoma mua.Ua hōʻike ʻia ka ʻikepili bioinformatics o ke ola Kaplan-Meier e pili ana ka ʻōlelo ACY3 kiʻekiʻe me ka prognosis maikaʻi ʻole, ʻoiai ʻo ka haʻahaʻa haʻahaʻa o ACY1 a i ʻole ASPA e pili ana me ka prognosis maikaʻi ʻole.Hōʻike kēia mau ʻikepili i ka dysregulated ka ʻōlelo aminoacylase i neuroblastoma